KARYOPHARM THERAPEUTICS INC's ticker is KPTI and the CUSIP is 48576U106. A total of 54 filers reported holding KARYOPHARM THERAPEUTICS INC in Q4 2013. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $144,295 | -80.4% | 166,315 | -65.9% | 0.00% | – |
Q1 2024 | $735,460 | +71.0% | 487,060 | -2.0% | 0.00% | – |
Q4 2023 | $430,080 | -50.9% | 497,202 | -23.9% | 0.00% | – |
Q3 2023 | $875,892 | -25.9% | 653,650 | -1.1% | 0.00% | – |
Q2 2023 | $1,182,503 | -33.1% | 660,616 | +45.4% | 0.00% | – |
Q1 2023 | $1,767,873 | +20.1% | 454,466 | +5.0% | 0.00% | – |
Q4 2022 | $1,471,796 | -9.8% | 432,881 | +44.8% | 0.00% | – |
Q3 2022 | $1,632,000 | +26.4% | 298,991 | +4.4% | 0.00% | – |
Q2 2022 | $1,291,000 | -41.0% | 286,381 | -3.5% | 0.00% | – |
Q1 2022 | $2,188,000 | +14.4% | 296,900 | -0.2% | 0.00% | – |
Q4 2021 | $1,913,000 | +8.7% | 297,541 | -1.6% | 0.00% | – |
Q3 2021 | $1,760,000 | -41.0% | 302,501 | +4.7% | 0.00% | -100.0% |
Q2 2021 | $2,983,000 | -11.4% | 289,056 | -9.6% | 0.00% | 0.0% |
Q1 2021 | $3,365,000 | -33.9% | 319,758 | -2.8% | 0.00% | 0.0% |
Q4 2020 | $5,093,000 | +0.7% | 328,960 | -5.1% | 0.00% | 0.0% |
Q3 2020 | $5,059,000 | -16.5% | 346,513 | +8.3% | 0.00% | -50.0% |
Q2 2020 | $6,062,000 | -3.6% | 320,014 | -2.3% | 0.00% | 0.0% |
Q1 2020 | $6,291,000 | +12.7% | 327,439 | +12.5% | 0.00% | +100.0% |
Q4 2019 | $5,580,000 | +141.3% | 291,093 | +21.1% | 0.00% | 0.0% |
Q3 2019 | $2,312,000 | +66.6% | 240,287 | +3.7% | 0.00% | – |
Q2 2019 | $1,388,000 | +8.5% | 231,640 | +5.8% | 0.00% | – |
Q1 2019 | $1,279,000 | -37.5% | 218,978 | +0.3% | 0.00% | -100.0% |
Q4 2018 | $2,047,000 | -45.0% | 218,412 | -0.1% | 0.00% | 0.0% |
Q3 2018 | $3,723,000 | +2.4% | 218,594 | +2.1% | 0.00% | 0.0% |
Q2 2018 | $3,636,000 | +62.1% | 214,018 | +28.1% | 0.00% | 0.0% |
Q1 2018 | $2,243,000 | +43.2% | 167,107 | +2.5% | 0.00% | – |
Q4 2017 | $1,566,000 | -13.0% | 163,093 | -0.4% | 0.00% | – |
Q3 2017 | $1,799,000 | +22.2% | 163,810 | +0.7% | 0.00% | – |
Q2 2017 | $1,472,000 | -36.9% | 162,678 | -10.4% | 0.00% | -100.0% |
Q1 2017 | $2,332,000 | +120.8% | 181,602 | +61.7% | 0.00% | – |
Q4 2016 | $1,056,000 | +23.7% | 112,287 | +27.9% | 0.00% | – |
Q3 2016 | $854,000 | +25.2% | 87,806 | -13.5% | 0.00% | – |
Q2 2016 | $682,000 | -21.5% | 101,558 | +4.3% | 0.00% | – |
Q1 2016 | $869,000 | -37.1% | 97,385 | -6.6% | 0.00% | – |
Q4 2015 | $1,382,000 | +25.6% | 104,297 | -0.2% | 0.00% | – |
Q3 2015 | $1,100,000 | -64.3% | 104,506 | -7.8% | 0.00% | -100.0% |
Q2 2015 | $3,083,000 | +24.1% | 113,305 | +39.6% | 0.00% | 0.0% |
Q1 2015 | $2,484,000 | +5.3% | 81,144 | +28.7% | 0.00% | 0.0% |
Q4 2014 | $2,359,000 | +7.4% | 63,025 | +0.2% | 0.00% | 0.0% |
Q3 2014 | $2,197,000 | -50.3% | 62,885 | -33.8% | 0.00% | 0.0% |
Q2 2014 | $4,420,000 | +161.1% | 94,946 | +73.2% | 0.00% | – |
Q1 2014 | $1,693,000 | +174.4% | 54,809 | +103.4% | 0.00% | – |
Q4 2013 | $617,000 | – | 26,941 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Delphi Management Partners VIII, L.L.C. | 2,263,006 | $13,170,000 | 9.51% |
Palo Alto Investors LP | 5,383,052 | $31,329,000 | 1.89% |
Birchview Capital, LP | 246,000 | $1,432,000 | 0.97% |
Lombard Odier Asset Management (Switzerland) SA | 1,517,804 | $8,834,000 | 0.55% |
Rubric Capital Management LP | 3,375,758 | $19,647,000 | 0.55% |
RICE HALL JAMES & ASSOCIATES, LLC | 1,401,861 | $8,159,000 | 0.30% |
AlphaCentric Advisors LLC | 136,000 | $792,000 | 0.20% |
Bridgefront Capital, LLC | 20,946 | $122,000 | 0.13% |
Hennion & Walsh Asset Management, Inc. | 407,474 | $2,371,000 | 0.12% |
Virtus ETF Advisers LLC | 44,364 | $258,000 | 0.11% |